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OBJECTIVES: A post-hoc sub-group analysis provides evidence that lacosamide
when used in conjunction with a non-sodium-channel blocking AED ismore effec-
tive than when used in combination with another sodium-channel blocking AED.
In order to allow patients earlier subsidised access to lacosamide (via the Pharma-
ceutical Benefits Scheme), a cost-effectiveness analysiswas conducted.METHODS:
Three large randomised, placebo controlled trials (SP667, SP754 and SP755) were
meta-analysed. More specifically, the analysis examined lacosamide used in con-
junction with a non-sodium channel AED (the sub-group) vs. lacosamide used in
conjunction with at least one sodium channel AED (the complement group). A deci-
sion tree (TreeAge) economic model reported the “cost per incremental 50% re-
sponder”. Lacosamide was utilised in the compliment group as a proxy for other
(similarly priced) adjunctive AED treatment. RESULTS: The meta-analysis, com-
pared those trial patients meeting the proposed PBS indication (the sub-group) to its
complement. More patients in the subgroup achieved a 50% reduction in seizure
frequency compared to the complement (51.1% vs. 34.7% respectively). Based on the
test of effect modification, there is a statistically meaningful effect modification
within the proposed subgroup (p0.03). The modelled incremental cost effective-
ness ICER, lacosamide (sub-group) costs $3064 per additional patient who achieves
at least a 50% reduction in seizures compared to the compliment. CONCLUSIONS:
A reimbursed listing on the PBS was sought which would limit the use of lacos-
amide to a refractory group and then only in combination with non-sodium AEDs.
Probabilistic sensitivity analysis was undertaken which showed that the PBAC
could be confident in that 68% of the outcomes are below $4000/responder. This
supported the robustness of the ICER. The analysis could have been strengthened
had it been based on a pre-specified analysis (and therefore randomised accord-
ingly), rather than on a post-hoc analysis.
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OBJECTIVES: To evaluate societal and economic benefits of self-administrated in-
jection of sumatriptan succinate compared to hospital-administrated one in the
treatment of acute severemigraine in Japan setting.METHODS:A cost-utility anal-
ysis (cost per QALY gained) by simulatingwith a 5-stateMarkovModel is conducted
from the societal perspective. Parameters incorporated into the model were taken
from literatures and the PMS of subcutaneous sumatriptan carried out in Japan.
Cost components incorporated into the model consist of migraine-related medical
costs, medicines, and transportation costs for traditional health care provider and
emergency room visits, calculating with Japan insurance-based medical fee
scheme for medical techniques and national health insurance price of medicines.
To assess robustness of a base case, univariate sensitivity analyses using tornado
diagram and probabilistic analysis using 10000-time Monte Carlo simulation were
performed. TreeAge Pro 2007 was used for the data analysis. RESULTS: At the base
case, it was deemed that use of self-administrated injection was less costly and
more effectiveness than hospital-administrated one. Univariate analyses revealed
that probability of onset of attack per week was identified as a cost driver. The
probabilistic analysis suggested that if willingness to pay on decision-making in
Japan setting was set at 5,000,000 JPY per QALY gained, approximately 100% of
probabilitywere obtained dominant consequences in a hypothetical cohort. There-
fore, it was demonstrated robustness of the base case analysis, retrospectively.
CONCLUSIONS: Thus, the aforementioned result suggested that the use of self-
administrated injection dominated hospital-administrated one irrespective of a
high initial price of self-administrated injection.
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OBJECTIVES:To evaluate the 10 year utilization trends of antiepileptic drugs (AEDs)
in Iran. METHODS: Annual pharmaceutical sales data were acquired from the
Ministry ofHealth (MOH). To express data, Anatomical Therapeutic Chemical (ATC)
classification and Defined Daily Dose (DDD) as described by WHO collaborating
centre for drug statistics methodology were used. DDD/1000 Inhabitants/Day (DID)
was the main unit for measuring drug sales and N03 was considered as AEDs here.
RESULTS: Between 2000 and 2010, the total consumption of antiepileptic drugs
increased by 49.85%, and reached 8.7 DDD/1000 inhabitants/day in 2010.Within the
studied ten years, the consumption of old AEDs increased by 9.6% (6.37 DDD/1000
inhabitants/d ay in 2010), while in the case of new AEDs the increase was 11432%
(2.37 DDD/1000 inhabitants/day). CONCLUSIONS: A significant shift can be seen in
the consumption of newAEDs. This change is partly due to the improved efficacy of
these drugs compared to the older types and referable to new indications to some
extent.
PND14
CHARACTERISTICS OF MULTIPLE SCLEROSIS PATIENTS WITH HIGH RELAPSE
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OBJECTIVES:Multiple sclerosis (MS) is a costly disease that affects adults. There are
very few studies evaluating the impact of high disease activity (HDA) on costs and
resource use using real world data. This study aims to compare demographics, cost
and resource utilization of MS patients with high and low annual relapses.
METHODS: A retrospective cross-sectional study was done using MarketScan®
commercial claim and Medicare database, 2009. Patients included had at least one
ICD-9 for MS (340.XX), were older than 18 years, and had continuous enrolment for
one year. HDA was defined as having two relapses annually, and relapse was de-
fined according to Chastek 2010 algorithm. Bivariate analysis were conducted to
compare HDA patients and other MS patients on patient characteristics, resource
utilization and costs (chi-square test for categorical variables and t-test for contin-
uous variables). RESULTS: A total of 22,170 patients met the study criteria. 94.58%
(N20,969) had less than two relapses and 5.42% (N1,201) had more than two
relapses in 2009. HDA patients were younger (49 vs. 52 years) and less likely to be
employed (50.54% vs. 56.12%). MS symptoms were more frequent in HDA group
including pain (54.87% vs. 39.55%), balance and coordination problems (24.23% vs.
10.72%) and fatigue (24.06% vs. 12.64%). HDA patients had more all cause and MS-
specific hospitalizations (26.39% vs. 12.59% and 15.24% vs. 1.62%) and ER visits
(39.88% vs.23.39% and 21.15% vs. 7.75%) compared to non-HDApatients. Mean total
cost (excluding DMT drug costs) for the HDA group was US$30,637 compared with
US$14,240 for the non-HDA group. p 0.0001 for all. CONCLUSIONS: Patients with
two or more relapses annually have high resource utilization and are more costly.
Two or more relapse annually seem to be indicative of high disease activity, how-
ever, amore robust algorithm needs to be validated to study such population using
claims database.
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OBJECTIVES: Chronic migraine (CM), defined as headache on at least 15 days per
month, with at least 8 days of migraine, is a sub-type of chronic daily headache
associated with significant quality of life (QoL) impairment. Clinical studies dem-
onstrate that botulinum toxin type A (BTX-A, 155-195U injected at specific head
and neck areas) results in clinically significant improvements in headache symp-
toms and QoL for CM patients. This study was conducted to obtain patient narra-
tives describing how response to BTX-A has benefited them in their daily lives.
METHODS: CM patients undergoing treatment with BTX-A were recruited via a
letter from their neurologist for in-depth interviews. The participants were ten
female chronic migraineurs who had suffered from migraines for 7-35 years, and
had received BTX-A treatment for 6 months to 5 years. RESULTS: For all partici-
pants, CMwas severely debilitating across all aspects of their lives including work/
study, family/personal relationships and social interactions. Some patients re-
ported prior symptoms of depression including suicidal ideation. The participants
had previously trialled numerous acute and prophylactic treatments but had ex-
perienced lack of efficacy, intolerance and rebound headaches from medication
overuse. Following treatment with BTX-A, participants reported reduced fre-
quency, severity and duration ofmigraines and headaches, increased dayswithout
acute medication intake, and improved response to simple analgesics. Personal
benefits included the ability to return to work or study, care for their children,
engage in social activities and take more active roles in the community. Partici-
pants felt that public reimbursement of BTX-A for CM would have a number of
positive outcomes including reduced financial stress of treatment for themselves
and their families, as well as potential cost reductions to the health care system
from decreased use of other medications and less hospitalisations and/or doctor
visits. CONCLUSIONS: CM patients responding to BTX-A prophylaxis report im-
proved symptoms and multiple QoL benefits.
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OBJECTIVES: Many studies as well as clinical experience indicate that moderate-
to-severe psoriasis is an emotionally and socially disabling disease. Themajority of
these studies, however, have been conducted in western countries, including Eu-
rope andNorth America. This study aimed to determine the burdens of psoriasis in
patients with psoriasis living in the Asia Pacific countries.METHODS:A systematic
literature search was conducted to identify evidence published between January
1990 and February 2012 evaluating the disease burdens, quality of life, and epide-
miology of psoriasis in Asia Pacific. RESULTS: Forty-five publications from China,
Hong Kong, India, Malaysia, Singapore, South Korea, and Taiwan were identified.
This literature demonstrated that psoriasis produces substantial impairments in
patients’ quality of life (QOL), and the level of impairment is dependent on the
patients’ disease severity. Across the retrieved literature, severely impaired quality
of life was observed in 19-39% of patients. The Dermatology Life Quality Index
(DLQI), a commonly used instrument to assess skin disease-specific QOL showed a
mean score of 6-20, indicating a moderate to very large effect of psoriasis on QOL.
Patients experienced difficulty in social life, daily activities, and reduced work
productivity. A higher Psoriasis Area and Severity Index (PASI) score (greater dis-
ease severity) was correlated with more impaired QOL. Psoriasis patients also suf-
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fered from high levels of anxiety, stress, and depression. The most frequent co-
morbidities included hypertension, coronary artery diseases, hyperlipidemia,
diabetes, obesity, depression, other skin diseases, and inflammatory bowel dis-
ease. Psoriasismay also confer an independent risk of acutemyocardial infarction.
CONCLUSIONS: Psoriasis was reported to have adverse effects on patients’ quality
of life including daily activities, social life, and productivity. Clinical burdens asso-
ciated with psoriasis included a number of serious co-morbidities. The evidence
retrieved as part of this systematic literature review well addressed the clinical
importance of psoriasis in Asia Pacific countries.
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OBJECTIVES: This study examined the opioid-sparing effectiveness, analgesic ef-
ficacy and tolerability of postoperative administration of parecoxib in total knee
arthroplasty (TKA) patients. METHODS: We performed a retrospective study of
enrollees received patient-controlled analgesia (PCA, consisted of morphine 1
mg/ml and fentanyl 30 mcg/ml) with or without single-dose of intravenous 40 mg
parecoxib following TKA from November 2010 through April 2011. Effect was as-
sessed by the amount of PCA used, pain intensity, length of hospital stay (LOS),
satisfaction score and adverse events. RESULTS: Nine patients under PCA with
parecoxib as the parecoxib group and 73 patients without parecoxib as the con-
trolled group were evaluated. PCA consumption was observed to be reduced in the
parecoxib group by 17.2 %, 25.5 % and 39.8 % less than the controlled group at 24 h,
48 h, and 72 h after surgery. Pain at movement improved significantly at 48 h and
72 h for the parecoxib group with visual analogue score (VAS). There were no
significant differences in pain scores at rest and LOS, however, between those who
received parecoxib or not. Satisfaction was described as “good, fair, and poor” by 0
%, 89%, and 11% in the parecoxib group, respectively, comparedwith 4%, 81%, and
15 % of the controlled group. The overall incidences of adverse events were re-
ported for 78 % of patients with parecoxib and 71 % of patients without parecoxib.
CONCLUSIONS: In this study, postoperative administration of parecoxib demon-
strated benefit in terms of PCA consumption and VAS score at movement. There-
fore, it seemed that parecoxib provided opioid-sparing and analgesic effect. Also,
the parental preparation of parecoxibmay be especially useful when patients were
unable to take oral medication or were experiencing nausea and vomiting.
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OBJECTIVES:Obesity and overweight constitute a significant public health issue in
New Zealand. The aim of this systematic review was to formally assess the evi-
dence on the effectiveness of selected obesity interventions. METHODS: The first
phase of this research involved a wide-ranging scoping search of the literature to
identify population-based obesity-prevention interventions. The search was con-
ducted using the Embase andMedline databases, a general internet search and via
the contributions of the stakeholder reference group. A total of 95 relevant primary
prevention interventionswere found, with 38 of these assessed in Australia or New
Zealand. The research team and the stakeholder reference group considered the
results of the scoping search and selected 16 interventions that appeared to be
effective using a weight-based outcome for full systematic review. RESULTS: The
selected interventions were based on both nutrition and physical activity in a
variety of age groups and settings (pre-school, school, tertiary education, commu-
nity, primary care and workplace). Interventions generally showed greater reduc-
tions in body mass index (BMI), BMI z-score, weight, weight to height ratio, waist
circumference and the incidence of being overweight or obese compared with
controls. In a school-basednutrition andphysical activity intervention inAustralia,
children in the intervention group gained significantly less weight compared with
the control group (-0.92 kg; P0.03). In a study of general health screening con-
ducted in Denmark, the body mass index of adults receiving the intervention in-
creased 0.6 kg/m2 less that those not receiving the intervention. CONCLUSIONS: A
number of interventions were shown to have the potential to prevent obesity in a
range of populations and settings. Themost cost-effective interventions for obesity
prevention were a school-based programme for children and general health
screening and advice for adults in a primary care setting.
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OBJECTIVES: Lead toxicity has been labeled as a major health problem globally
with limited therapeutic options. Literature reveals controversial reports on the
lead detoxifying potential of ascorbic acid (vitamin C). The aim of this study was to
see if vitamin C supplementation reduces lead levels of blood in adult subjects
exposed to lead.METHODS:After ethical approval and informed consent the traffic
police study subjects (all male) were randomly divided into two groups each con-
taining 40 subjects. One group received 500 mg vitamin C, while the second group
was given 1000 mg orally daily for a period of one month. Blood samples were
collected at 0, 15, and 30 days of treatment and lead levels were analyzed from the
PCSIR Lab, Karachi using atomic absorption spectrophotometer. RESULTS: The
data showed raised levels of lead in study subjects of both groups (21.74 1.62 and
22.51  1.28 mcg/dl; mean  SEM; N40) compared to the safe limit ( 10 mcg/dl)
recommended by WHO. The treatment with vitamin C (500 mg) reduced the lead
levels to 16.91 1.08mcg/dl (N29) after 15 days treatment (P0.01), while the lead
level after 30 days treatment was further reduced to12.61  1.50 mcg/dl (N  36;
p0.001 compared to control, 21.74  1.62). In the second group subjects, which
received 1000 mg vitamin C, the lead level after 15 days treatment was 15.800.89
mcg/dl (N 33; P0.001)), with no further drop (P0.05) after 30 days treatment, as
the resultant lead levelwas 14.64 1.05mcg/dl (N31).CONCLUSIONS:These data
indicate that vitamin C has a dose and time-dependent lead-detoxifying effect and
that vitamin C supplementation may be an effective, safe and economical method
in reducing blood lead levels in chronically exposed subjects such as traffic police.
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OBJECTIVES:A validated screening tool for the diagnosis of fibromyalgia (ACR 2010
FM-STD) had been introduced in Thailand. The aim of this study is to explore with
the FM-STD the prevalence of fibromyalgia (FM) and estimate its burden of disease
(BOD) within the community of Bangkok, Thailand. METHODS: A cross-sectional
nonclinical survey process was conducted in urban and suburban Bangkok during
August-December 2011. The questionnaire was designed to collect data related to
pain, likelihood of FM diagnose, pain impact and treatment patterns. Primary in-
terviewswere conducted by field researchers. Every respondent, whose scoresmet
the diagnostic criteria of FM,were subsequently referred to further investigation by
our research physicians who confirmed final diagnoses of those cases. RESULTS:
One thousand respondents fromvarious socio-economic backgrounds participated
in the survey. Six of them (0.6%) were medically found positive to FM; their mean
age (range): was 47.67 (33-63) years. Mean widespread pain index (WPI) and symp-
tom severity (SS) scale score (range): 10.17 (7-16) and 7.83 (7-12), respectively. Lower
back and right shoulder girdle were the first and second most frequent pain loca-
tions. Intermittent throbbing pain was the most general presentation among FM
cases. For key FM features, all six respondents reported, mild to severe intensity
fatigue and waking unrefreshed while altogether cognitive impairment was re-
ported unproblematic. Furthermore, FM had strong impact to daily activities, par-
ticularly for sleep, walk and routine work. Mean ability to accomplish work de-
clined up to 71.67% (60%-90%). All cases required aminimum onemonthly therapy
to manage their pain symptoms; massage/spa being the most frequent treatment
method selected in this study. Average monthly out-of-pocket expense, related to
pain management was US$16.11 (0-33.33). CONCLUSIONS: This is the first epide-
miological survey of FM in Thailand. Therefore, study’s findings will generate a
better understanding of FM problem among Thai health care providers.
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OBJECTIVES: To describe the prevalence and treatment status of hemophilia A
(HA), hemophilia B (HB), hemophilia C (HC) and Von Willebrand disease (VWD) in
mainland China based on existing data, and to estimate the cost of switching from
on-demand therapy to prophylaxis.METHODS:We conducted a systematic litera-
ture review in Aug, 2011 using PubMed, EMBASE, and Cochrane Library in English
and CBM, CNKI, VIP, Wanfang Database in Chinese. No retrieval limitation was set.
In addition, we carried out a search of general and targeted hemophilia related
websites. Reference lists of key reviews were hand-searched for further relevant
researches. Studies providing data of prevalence or cost of hemophilia inmainland
China were included. Meta-analysis was done using the generic inverse variance
model. RESULTS: 22 epidemiological and 16 economic studies were included for
the analysis. The weighted prevalence of hemophilia (HAHBHCVWD) was 3.6
per 100,000 (95%CI: 2.7-4.9 per 100 000).We estimated the number of hemophiliac in
mainland china to be 49,339 based on the data from the 6th nationwide census. The
official registration number of hemophiliac now is 9804. More than 50% of hemo-
philiacs inmainlandChinawere un-treated or treated occasionally. In the choice of
treating product, less than 50% used pure blood coagulation factors. Less than 10%
received prophylaxis. Based on the cost-effective study, low dose prophylaxis was
a cost-saving strategy compared to on-demand therapy. The frequency of bleeding
could be reduced by 80% and the life of hemophiliac would be close to normal if
extra CNY2.66 billion (CNY53845per case) were invested every year.
CONCLUSIONS: The prevalence of hemophilia in mainland China is underesti-
mated. Registration management has to be improved. Patients with hemophilia
lack treatment generally. It is practical to consider switching the treatment of
hemophilia from on-demand therapy to low dose prophylaxis.
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IMPACT OF ANTI-VIRAL TREATMENT ON THE ECONOMIC BURDEN OF CHRONIC
HEPATITIS B IN TAIWAN
Chen PJ1, Chen CJ2, Yang HI3, McLeod E4, Heatley R5
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